AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Peripheral T-Cell Lymphoma in 2026: Reclassification, BV-CHP as Standard, and a Pipeline Finally Targeting Disease Biology
By Ranjit Nair, MD
Peripheral T-cell lymphomas are among the most challenging malignancies in hematologic oncology.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Bispecific Antibodies and Fixed-Duration CLL Therapy: The Lymphoma and CLL Landscape in 2026
By Jennifer Huang, PhD, MD
The 2026 lymphoma and CLL landscape is defined by maturing long-term data, the shift of bispecific antibodies into earlier treatment lines, and the emergence of all-oral, fixed-duration regimens.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Early-Stage Lung Cancer in 2026: Why Detection Still Changes Everything
By Thomas Templin, MD MBA
Lung cancer remains the world’s leading cause of cancer death. Reducing tobacco use has helped, but it has not solved the problem.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
Soy and Breast Cancer: Is It Safe to Eat Tofu?
By Ariana Sutherland
Tofu has a reputation for raising estrogen levels—but the science tells a different story. An oncologist explains why soy's isoflavones may actually behave more like estrogen blockers than estrogen itself.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and What's Actually Changing in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and What's Actually Changing in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
Targeted Therapy Arrives in Neuro-Oncology: Vorasidenib, Dordaviprone, and What's Actually Changing in Brain Tumor Care
By Toni Cao, MD
Neuro-oncology has long been one of the last fields to benefit from the precision medicine revolution.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant's Role Is fading, BTKi Combinations Are Frontline, and Brexu-cel Has Five-Year Data in RR-MCL
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line, Maintenance Gets Smarter, and Early Disease Is Changing Fast with TDxd neoadjuvant and adjuvant approvals
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
CAR-T Cell Therapy in Follicular Lymphoma and CLL: Identifying the High-Risk Patients Who Need It Most
By Bradley W. Christensen, MD
Expert commentary on CAR-T therapy for follicular lymphoma and CLL, focusing on POD24 patients, FLIPI-2 risk, bispecific antibodies, and emerging treatment strategies.
CAR-T Cell Therapy in Follicular Lymphoma and CLL: Identifying the High-Risk Patients Who Need It Most
By Bradley W. Christensen, MD
Expert commentary on CAR-T therapy for follicular lymphoma and CLL, focusing on POD24 patients, FLIPI-2 risk, bispecific antibodies, and emerging treatment strategies.
CAR-T Cell Therapy in Follicular Lymphoma and CLL: Identifying the High-Risk Patients Who Need It Most
By Bradley W. Christensen, MD
Expert commentary on CAR-T therapy for follicular lymphoma and CLL, focusing on POD24 patients, FLIPI-2 risk, bispecific antibodies, and emerging treatment strategies.
The Hidden Barrier to Precision Oncology: How Insurance Policies Delay Access to Genomic Testing
By Ira Klein, MBA, MD, FACP
Dr. Ira Klein explores how outdated insurance policies, prior authorization burdens, and administrative barriers delay equitable access to precision oncology testing.
The Hidden Barrier to Precision Oncology: How Insurance Policies Delay Access to Genomic Testing
By Ira Klein, MBA, MD, FACP
Dr. Ira Klein explores how outdated insurance policies, prior authorization burdens, and administrative barriers delay equitable access to precision oncology testing.
The Hidden Barrier to Precision Oncology: How Insurance Policies Delay Access to Genomic Testing
By Ira Klein, MBA, MD, FACP
Dr. Ira Klein explores how outdated insurance policies, prior authorization burdens, and administrative barriers delay equitable access to precision oncology testing.
AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself
By Benjamin O. Anderson, MD, FACS
Dr. Benjamin O. Anderson explores the promise and limitations of AI in breast diagnostics, emphasizing that patient navigation, infrastructure, and access to care matter more than technology alone.
AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself
By Benjamin O. Anderson, MD, FACS
Dr. Benjamin O. Anderson explores the promise and limitations of AI in breast diagnostics, emphasizing that patient navigation, infrastructure, and access to care matter more than technology alone.
AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself
By Benjamin O. Anderson, MD, FACS
Dr. Benjamin O. Anderson explores the promise and limitations of AI in breast diagnostics, emphasizing that patient navigation, infrastructure, and access to care matter more than technology alone.